| Literature DB >> 25171741 |
Harriet Mpairwe1, Juliet Ndibazza, Emily L Webb, Margaret Nampijja, Lawrence Muhangi, Barbara Apule, Swaib Lule, Hellen Akurut, Dennison Kizito, Mohammed Kakande, Frances M Jones, Colin M Fitzsimmons, Moses Muwanga, Laura C Rodrigues, David W Dunne, Alison M Elliott.
Abstract
BACKGROUND: Worms may protect against allergy. Early-life worm exposure may be critical, but this has not been fully investigated.Entities:
Keywords: IgE; Uganda; birth cohort; children; eczema; effect modification; hookworm; incidence; pregnancy; skin prick test
Mesh:
Substances:
Year: 2014 PMID: 25171741 PMCID: PMC4312885 DOI: 10.1111/pai.12251
Source DB: PubMed Journal: Pediatr Allergy Immunol ISSN: 0905-6157 Impact factor: 6.377
Maternal factors and their association with childhood eczema in the first five years of life
| Maternal factor | Number of children in each category (%) | No of eczema events | Person-years at risk (×100) | Rate (per 100 pyrs) | Crude HR (95% CI) | aHR | p-value |
|---|---|---|---|---|---|---|---|
| Education | |||||||
| None/primary | 1278 (55) | 232 | 51.65 | 4.49 | 1 | 1 | 0.85 |
| Post-primary | 1063 (45) | 220 | 44.63 | 4.93 | 1.11 (0.84–1.54) | 0.97 (0.70–1.35) | |
| Household socio-economic status | |||||||
| Lower status | 1053 (46) | 164 | 42.78 | 3.83 | 1 | 1 | 0.08 |
| Higher status | 1248 (54) | 274 | 51.89 | 5.28 | 1.39 (0.99–1.96) | 1.36 (0.96–1.92) | |
| Area of residence | |||||||
| Entebbe, town | 950 (41) | 251 | 38.74 | 6.48 | 1 | 1 | 0.002 |
| Kiggungu, fishing village | 261 (11) | 18 | 11.25 | 1.60 | 0.25 (0.14–0.43) | 0.27 (0.15–0.46) | |
| Manyago and Kabale, peri-urban | 651 (28) | 131 | 26.89 | 4.87 | 0.75 (0.53–1.07) | 0.76 (0.52–1.10) | |
| Katabi, rural | 451 (20) | 48 | 18.48 | 2.60 | 0.40 (0.25–0.66) | 0.42 (0.25–0.68) | |
| Regular cigarette smoking by adult in house | |||||||
| No | 1429 (81) | 320 | 66.18 | 4.83 | 1 | 1 | 0.56 |
| Yes | 330 (19) | 81 | 14.98 | 5.41 | 1.11 (0.64–1.92) | 1.17 (0.69–1.99) | |
| Maternal history of asthma | |||||||
| None | 1706 (97) | 382 | 78.66 | 4.86 | 1 | 1 | 0.26 |
| Yes | 60 (3) | 19 | 2.84 | 6.70 | 1.40 (0.73–2.70) | 1.44 (0.76–2.74) | |
| Maternal history of eczema | |||||||
| None | 1710 (97) | 374 | 78.94 | 4.74 | 1 | 1 | 0.02 |
| Yes | 56 (3) | 27 | 2.55 | 10.59 | 2.24 (1.12–4.47) | 2.28 (1.14–4.53) | |
| Maternal albendazole trial arm during pregnancy | |||||||
| Placebo arm | 1175 (50) | 175 | 48.21 | 3.63 | 1 | – | 0.005 |
| Albendazole arm | 1170 (50) | 277 | 48.26 | 5.74 | 1.58 (1.15–2.17) | ||
| Maternal worm infections during pregnancy | |||||||
| 1. Hookworm | 1311 (56) | 298 | 54.34 | 5.48 | 1 | 1 | 0.04 |
| Yes | 1025 (44) | 151 | 41.78 | 3.61 | 0.65 (0.48–0.90) | 0.71 (0.51–0.99) | |
| 2 | 1841 (79) | 389 | 75.85 | 5.13 | 1 | 1 | 0.10 |
| Yes | 496 (21) | 63 | 20.32 | 3.10 | 0.60 (0.39–0.92) | 0.70 (0.45–1.07) | |
| 3 | 1915 (82) | 381 | 78.56 | 4.85 | 1 | 1 | 0.51 |
| Yes | 421 (18) | 68 | 17.55 | 3.87 | 0.80 (0.55–1.15) | 0.88 (0.61–1.28) | |
| 4. | 2041 (88) | 380 | 84.03 | 4.52 | 1 | 1 | 0.33 |
| Yes | 283 (12) | 65 | 11.60 | 5.60 | 1.23 (0.77–1.95) | 1.27 (0.78–2.06) | |
| 5. | 2130 (91) | 422 | 87.81 | 4.81 | 1 | 1 | 0.59 |
| Yes | 206 (9) | 27 | 8.30 | 3.25 | 0.67 (0.24–1.86) | 0.73 (0.23–2.33) | |
| 6. | 2282 (98) | 466 | 93.87 | 4.75 | 1 | 1 | 0.08 |
| Yes | 54 (2) | 3 | 2.25 | 1.33 | 0.28 (0.09–0.87) | 0.37 (0.12–1.14) | |
| Hookworm category | |||||||
| None | 1311 (56) | 298 | 54.34 | 5.48 | 1 | 1 | 0.03 |
| Mild | 872 (37) | 134 | 35.70 | 3.75 | 0.68 (0.49–0.95) | 0.74 (0.53–1.04) | |
| Mod-severe | 153 (7) | 17 | 6.08 | 2.79 | 0.51 (0.27–0.96) | 0.56 (0.30–1.07) | |
| Maternal asymptomatic malaria during pregnancy | |||||||
| None | 2037 (88) | 414 | 84.23 | 4.91 | 1 | 1 | 0.03 |
| Yes | 266 (12) | 34 | 10.64 | 3.20 | 0.65 (0.41–1.02) | 0.59 (0.37–0.95) | |
Pyrs, person years; CI, confidence interval; HR, hazard ratio; aHR, adjusted hazard ratio.
Adjusted for maternal education, area of residence and household socio-economic status.
No of missing variables:
= 4,
‡ = 44,
= 32,
= 586,
= 579,
= 579,
= 9,
= 8,
= 21,
= 42.
Childhood factors associated with eczema in the first five years of life
| Childhood factor | Number of children in each category (%) | No of eczema events | Person-years at risk (×100) | Rate (per 100 pyrs) | Crude HR (95% CI) | aHR | p-value |
|---|---|---|---|---|---|---|---|
| Child's birth order | |||||||
| First born | 622 (27) | 108 | 24.25 | 4.45 | 1 | 1 | 0.06 |
| 2nd–4th born | 1342 (57) | 257 | 55.91 | 4.60 | 1.05 (0.72–1.53) | 1.07 (0.73–1.58) | |
| 5th born or more | 381 (16) | 87 | 16.31 | 5.33 | 1.22 (0.73–2.05) | 1.37 (0.82–2.27) | |
| Child's birth weight | |||||||
| Normal | 1719 (90) | 368 | 71.70 | 5.13 | 1 | 1 | 0.48 |
| Low (≤2.5 kg) | 187 (10) | 31 | 7.50 | 4.13 | 0.81 (0.43–1.51) | 0.79 (0.41–1.51) | |
| Child's sex | |||||||
| Male | 1208 (52) | 193 | 49.75 | 3.88 | 1 | – | 0.03 |
| Female | 1135 (48) | 259 | 46.72 | 5.54 | 1.43 (1.04–1.97) | – | |
| Common childhood infections diagnosed prospectively (0–5 yr) | |||||||
| 1. Malaria | |||||||
| Mean (range) of episodes: 1.4 (0–16) | – | – | – | 0.94 (0.88–1.00) | 0.88 (0.83–0.94) | <0.0001 | |
| 2. Diarrhoea | |||||||
| Mean (range) of episodes: 2.6 (0–22) | – | – | – | 1.10 (1.05–1.16) | 1.02 (0.93–1.10) | 0.71 | |
| 3. Lower respiratory infections | |||||||
| Mean (range) of episodes: 0.4 (0–9) | – | – | – | 1.25 (1.11–1.41) | 1.10 (0.96–1.26) | 0.18 | |
| 4. Upper respiratory infections | |||||||
| Mean (range) of episodes: 11 (0–58) | – | – | – | 1.04 (1.03–1.06) | 1.00 (0.95–1.04) | 0.92 | |
| Childhood worm infections | |||||||
| 1. | 643 (79) | 179 | 32.08 | 5.58 | 1 | 1 | 0.002 |
| Yes | 167 (21) | 16 | 8.13 | 1.97 | 0.35 (0.18–0.66) | 0.35 (0.18–0.67) | |
| 2. | 680 (89) | 180 | 33.93 | 5.30 | 1 | 1 | 0.22 |
| Yes | 85 (11) | 12 | 4.11 | 2.92 | 0.54 (0.28–1.06) | 0.64 (0.32–1.30) | |
| 3 | 700 (93) | 177 | 34.93 | 5.07 | 1 | 1 | 0.45 |
| Yes | 56 (7) | 14 | 2.70 | 5.19 | 1.00 (0.34–2.97) | 1.55 (0.50–4.81) | |
| 4. Hookworm (747): None | 705 (94) | 185 | 35.18 | 5.26 | 1 | 1 | 0.05 |
| Yes | 42 (6) | 4 | 1.99 | 2.01 | 0.37 (0.14–0.98) | 0.33 (0.11–1.02) | |
| 5. | 839 (97) | 206 | 41.87 | 4.92 | 1 | 1 | 0.28 |
| Yes | 25 (3) | 9 | 1.14 | 7.86 | 1.54 (0.66–3.59) | 1.60 (0.68–3.77) | |
| Child's atopic status (assessed at 3 yr) | |||||||
| Skin prick responses (569) | |||||||
| Negative | 464 (82) | 67 | 22.71 | 2.95 | 1 | – | <0.0001 |
| Positive | 105 (18) | 49 | 5.08 | 9.65 | 3.26 (1.84–5.80) | – | |
| Dermatophagoides-specific IgE (540) | |||||||
| Non-atopic | 478 (89) | 93 | 23.34 | 3.98 | 1 | – | 0.21 |
| Atopic | 62 (11) | 20 | 3.02 | 6.62 | 1.66 (0.75–3.69) | – | |
| Cockroach-specific IgE (540) | |||||||
| Non-atopic | 448 (83) | 91 | 21.90 | 4.15 | 1 | – | 0.67 |
| Atopic | 92 (17) | 22 | 4.46 | 4.94 | 1.18 (0.55–2.55) | – | |
Pyrs, person years; CI, confidence interval; HR, hazard ratio; aHR, adjusted hazard ratio.
For categorical variables, this is the p-value for the test of trend.
Adjusted for maternal education, area of residence and household socio-economic status; childhood illnesses were additionally adjusted for the total number of clinic visits a child made during the study period. Breastfeeding was not adjusted for as 98% of the children in this study were breastfed.
Children with data on worm infections at all five annual visits were included for this analysis.
Three-year-old children seen between November 2007 and March 2009 were selected for skin prick tests (4 allergens) and allergen-specific IgE testing.
No of missing variables:
= 430,
= 2.
The interaction of maternal hookworm infection during pregnancy with the other risk factors for eczema in the first five years of life
| Maternal hookworm status | Number (%) with given risk factor | No. of eczema events | Person years at risk (×100) | Rate (per 100 pyrs) | Crude HR (95% CI) | aHR | p-value | Test for interaction p-value |
|---|---|---|---|---|---|---|---|---|
| Maternal history of eczema (1766) | ||||||||
| None | No 955 (96) | 240 | 44.33 | 5.41 | 1 | 1 | 0.008 | 0.05 |
| Yes 35 (4) | 24 | 1.60 | 14.96 | 2.78 (1.29–6.00) | 2.87 (1.31–6.27) | |||
| Yes | No 751 (97) | 131 | 34.42 | 3.81 | 1 | 1 | 0.60 | |
| Yes 21 (3) | 3 | 0.95 | 3.17 | 0.83 (0.28–2.42) | 0.73 (0.23–2.30) | |||
| Maternal albendazole during pregnancy (2345) | ||||||||
| None | Placebo 643(49) | 103 | 26.65 | 3.86 | 1 | – | 0.006 | 0.15 |
| Albendazole 668 (51) | 195 | 27.68 | 7.04 | 1.82 (1.19–2.79) | – | |||
| Yes | Placebo 528 (52) | 72 | 21.41 | 3.36 | 1 | – | 0.56 | |
| Albendazole 497 (48) | 79 | 20.37 | 3.88 | 1.15 (0.72–1.83) | – | |||
| Child's gender (2334) | ||||||||
| None | Male 695 (53) | 113 | 28.46 | 3.97 | 1 | – | 0.004 | 0.04 |
| Female 614 (47) | 185 | 25.87 | 7.15 | 1.82 (1.22–2.73) | – | |||
| Yes | Male 506 (49) | 77 | 20.94 | 3.68 | 1 | – | 0.87 | |
| Female 519 (51) | 74 | 20.84 | 3.55 | 0.96 (0.60–1.53) | – | |||
| Child's skin prick test positive responses (569) | ||||||||
| None | Negative 264 (79) | 28 | 12.93 | 2.16 | 1 | – | <0.0001 | 0.18 |
| Positive 70 (21) | 35 | 3.41 | 10.27 | 4.74 (2.30–9.73) | – | |||
| Yes | Negative 199 (85) | 37 | 9.73 | 3.80 | 1 | – | 0.08 | |
| Positive 35 (15) | 14 | 1.67 | 8.37 | 2.20 (0.92–5.26) | – | |||
| Child's dermatophagoides mix-specific IgE responses (539) | ||||||||
| None | Non-atopic 276 (87) | 45 | 13.50 | 3.33 | 1 | – | 0.03 | 0.03 |
| Atopic 41 (13) | 18 | 1.98 | 9.07 | 2.72 (1.11–6.63) | – | |||
| Yes | Non-atopic 201 (91) | 46 | 9.79 | 4.70 | 1 | – | 0.22 | |
| Atopic 21 (9) | 2 | 1.04 | 1.93 | 0.41 (0.10–1.69) | – | |||
| Child's German cockroach-specific IgE responses (539) | ||||||||
| None | Non-atopic 258 (81) | 43 | 12.64 | 3.40 | 1 | – | 0.10 | 0.01 |
| Atopic 59 (19) | 20 | 2.84 | 7.04 | 2.06 (0.87–4.85) | – | |||
| Yes | Non-atopic 189 (85) | 46 | 9.21 | 4.99 | 1 | – | 0.06 | |
| Atopic 33 (15) | 2 | 1.62 | 1.24 | 0.25 (0.06–1.04) | – | |||
Pyrs, person years; CI, confidence interval; HR, hazard ratio; aHR, adjusted hazard ratio.
Adjusted for maternal education, area of residence and household socio-economic status.
Three-year-old children seen between November 2007 and March 2009 were selected for r skin prick tests (4 allergens) and allergen-specific IgE testing.